Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 in “NEO-CYT” trial in High-Risk, Surgically Resectable Neoadjuvant Stage III Melanoma
Professor Paolo A. Ascierto, Lead Principal Investigator of NEO-CYT, commented: “Neoadjuvant therapy has taught us that timing of immunotherapy matters. Treating patients undergoing curative surgery while the tumor is still present can generate deeper and more durable immune responses. Advancing into the neoadjuvant setting represents a logical next-step in clinical development of any promising immunotherapy by treating earlier-stage, high-risk patients. Importantly, NEO-CYT is designed to evaluate combinations of MDNA11 with two major immunotherapies, nivolumab with or without ipilimumab. NEO‑CYT will test whether adding a next-generation IL-2 superkine, MDNA11, to proven checkpoint combinations in resectable, high-risk melanoma can improve pathologic responses with the potential to improve curative benefit after surgery.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the